The plasma protease C1-inhibitor treatment market has been gaining huge traction over the years owing to growing cases of hereditary angioedema (HAE) globally. C1-inhibitor therapies work by inhibiting the activation of the complement and contact kinin pathways of the immune system and are used to prevent or treat swelling related to HAE. The therapies include plasma-derived C1-inhibitor concentrates like Berinert, Cinryze, and Haegarda that are administered intravenously during HAE attacks. These therapies offer advantages like easy administration, help reduce attack frequency and severity, and are considered safe and well-tolerated options for long-term prophylaxis in HAE patients. The increasing diagnosis rate and approval of new therapies are expected to further fuel the demand for plasma protease C1-inhibitor treatment.
The Global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the plasma protease C1-inhibitor treatment market are R&D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble are among the major participants. These companies offer a wide range of plasma-derived C1-inhibitor replacement therapies and focus on expanding their product portfolio through strategic collaborations and mergers.
The Plasma Protease C1-Inhibitor Treatment Market Size is driven by the growing prevalence of hereditary angioedema (HAE) globally. According to estimates, about 1 in 10,000 to 1 in 50,000 people suffer from HAE worldwide. Favorable reimbursement policies for C1-inhibitor therapies in developed nations are also contributing to the increasing adoption.
Technological advancements include the development of next-generation recombinant C1-inhibitor therapies with improved pharmacokinetic profiles. Companies are conducting late-stage clinical trials to evaluate the efficacy, safety, and convenience of recombinant therapies in preventing HAE attacks. This will offer patients more treatment choices in the coming years.
Market Trends
1. Increased uptake of subcutaneous C1-inhibitor concentrates: Ease of self-administration of subcutaneous products compared to intravenous formulations is a key driver of uptake. Haegarda and Takhzyro are preferred due to longer half-life and less frequent dosing needs.
2. Shift towards extended half-life therapies: With advantages like less frequent dosing, companies are focusing on developing next-gen products with improved pharmacokinetics. Investigational therapies like BCX7353 have half-lives over 7 days.
Market Opportunities
1. Emerging markets: Asia Pacific and Latin America regions present high opportunities due to rising healthcare infrastructure and expenditures in these markets. Entry of leading global players will drive market growth.
2. Recombinant product approvals: Approval of recombinant C1-inhibitor therapies currently in trials, such as SOBCI from Pharming, will offer safe and convenient new options to manage HAE attacks.
Impact of COVID-19 on Plasma Protease C1-inhibitor Treatment Market Growth
The COVID-19 pandemic severely impacted the growth of the plasma protease C1-inhibitor treatment market. During the initial months of the outbreak when lockdowns were imposed, there was a significant decline in new screening and diagnosis of hereditary angioedema. Several scheduled treatments and procedures were either postponed or canceled to avoid potential exposure to COVID-19 in hospitals and clinics. This negatively affected the demand for plasma protease C1-inhibitor treatment drugs in the short term. However, with rising awareness about the importance of continuing treatment for chronic conditions, the market is recovering gradually post lockdowns. Telemedicine and home healthcare are helping more patients obtain plasma protease C1-inhibitor treatment drugs while staying safe at home during the pandemic. Manufacturers are focusing on ensuring adequate supply through strategic production and transportation planning to address any future disruptions. Overall, while COVID-19 posed initial challenges, the long term outlook remains positive due to growing diagnosis rates and new product launches.
Geographical Regions with High Concentration in Plasma Protease C1-inhibitor Treatment Market
North America currently accounts for the largest share of the global plasma protease C1-inhibitor treatment market in terms of value. This is attributed to factors such as early diagnosis, treatment seeking rate, favorable reimbursement policies, and presence of major market players in the region. Within North America, the United States is the major revenue generator owing to high incidence of hereditary angioedema. Europe is the second largest regional market boosted by rising public health awareness initiatives by government agencies. Countries like Germany, France and United Kingdom have emerged as high potential markets in Europe. The Asia Pacific region is expected to offer lucrative growth opportunities for plasma protease C1-inhibitor treatment manufacturers over the forecast period due to rapidly improving accessibility to healthcare services. China and India represent emerging Asian markets with high unmet needs.
Fastest Growing Region in the Plasma Protease C1-inhibitor Treatment Market
The Asia Pacific region holds tremendous growth potential for the plasma protease C1-inhibitor treatment market and is estimated to rise at the fastest CAGR between 2024-2031. Factors such as rising healthcare investments, increasing per capita incomes, growing baby boomer population susceptible to hereditary angioedema, and expansion of healthcare infrastructure are fueling the demand in the Asia Pacific region. Additionally, several international companies are shifting their manufacturing base to countries like India and China due to availability of low cost skilled labor and land, which is positively impacting market growth. Awareness programs by NGOs and government initiatives to promote generic drugs are further supporting the market penetration in Asia Pacific’s developing nations.
Get more insights on This Topic- Plasma Protease C1-Inhibitor Treatment Market